ECHELON-2 is the first randomized phase 3 study establishing the superiority of BV-CHP over CHOP in untreated PTCL, which led to FDA approval in November 2018 of BV-CHP as frontline therapy for CD30-positive PTCL. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.